New antimicrobial agents for methicillin-resistant Staphylococcus aureus.

In bacterial and fungal infections, optimal outcomes are obtained through the timely provision of adequate antimicrobial coverage in an initial anti-infective treatment regimen. However, selecting appropriate antimicrobial regimens to treat infections in the intensive care unit is challenging because of the expansion of antibiotic resistance. Multidrug anti-infective regimens are typically needed to adequately cover common important pathogens in ICUs. Here, we describe novel antibacterial agents in the late stages of clinical development that show potential for treating methicillin-resistant Staphylococcus aureus (MRSA) infections. These include the fifth-generation cephalosporins, ceftaroline and ceftobiprole; the glycopeptides, dalbavancin, oritavancin, and telavancin; and iclaprim.

[1]  Ronald N. Jones,et al.  Antimicrobial activity of ceftobiprole, a novel anti-methicillin-resistant Staphylococcus aureus cephalosporin, tested against contemporary pathogens: results from the SENTRY Antimicrobial Surveillance Program (2005-2006). , 2008, Diagnostic microbiology and infectious disease.

[2]  G. Talbot,et al.  Phase 2 Study of Ceftaroline versus Standard Therapy in Treatment of Complicated Skin and Skin Structure Infections , 2007, Antimicrobial Agents and Chemotherapy.

[3]  W. O'Riordan,et al.  Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[4]  G. Talbot,et al.  In Vitro Profiling of Ceftaroline against a Collection of Recent Bacterial Clinical Isolates from across the United States , 2008, Antimicrobial Agents and Chemotherapy.

[5]  J. Solomkin,et al.  Results of a Double-Blind, Randomized Trial of Ceftobiprole Treatment of Complicated Skin and Skin Structure Infections Caused by Gram-Positive Bacteria , 2007, Antimicrobial Agents and Chemotherapy.

[6]  J. Karlowsky,et al.  Dalbavancin and telavancin: novel lipoglycopeptides for the treatment of Gram-positive infections , 2008, Expert review of anti-infective therapy.

[7]  B. Goldstein,et al.  Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infections. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[8]  B. Goldstein,et al.  Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by gram-positive pathogens. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[9]  L. Dunbar,et al.  A review of telavancin in the treatment of complicated skin and skin structure infections (cSSSI) , 2008, Therapeutics and clinical risk management.

[10]  Steven N. Leonard,et al.  Telavancin: An Antimicrobial with a Multifunctional Mechanism of Action for the Treatment of Serious Gram‐Positive Infections , 2008, Pharmacotherapy.

[11]  K. Bush,et al.  A randomized, double-blind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime for the treatment of patients with complicated skin and skin-structure infections. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[12]  J. Andrews,et al.  Concentrations in plasma, epithelial lining fluid, alveolar macrophages and bronchial mucosa after a single intravenous dose of 1.6 mg/kg of iclaprim (AR-100) in healthy men. , 2007, The Journal of antimicrobial chemotherapy.